Biotech Soars On Material Transfer Agreement

2024-09-24 07:00:04

(MENAFN- Yolo Wire) A New York-based %Biotech company is turning heads on Tuesday after it announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense’s military and veterans adaptive platform clinical trial for PTSD.

Traders were quick to snatch up shares of %SeelosTherapeutics Inc. (Nasdaq: $SEEL), pushing the price of this micro cap up to $0.5536/share (+191.37%) at the early session high. This move could be indicative of a potential breakout for this stock in sessions to come!

Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address significant unmet needs in the Central Nervous System (CNS) disorders and other rare disorders.

MENAFN24092024007606016353ID1108711293

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.